# Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma

> **NCT05998642** · PHASE2 · RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 30 (estimated)

## Conditions studied

- Non-hodgkin Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Rituximab (where available)
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT05998642
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-13
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05998642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05998642, "Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05998642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*